

RESEARCH ARTICLE

Open Access



Risk factors and implications of progressive coronary dilatation in children with Kawasaki disease

Ming-Yu Liu¹, Hsin-Min Liu¹, Chia-Hui Wu¹, Chin-Hao Chang², Guan-Jr Huang³, Chun-An Chen¹, Shuenn-Nan Chiu¹, Chun-Wei Lu¹, Ming-Tai Lin^{1*} , Luan-Yin Chang¹, Jou-Kou Wang¹ and Mei-Hwan Wu¹

Abstract

Background: Kawasaki disease (KD) is an acute systemic vasculitis that occurs in children and may lead to cardiovascular morbidity and mortality. Progressive coronary dilatation for at least 2 months is associated with worse late coronary outcomes in patients with KD having medium or giant aneurysms. However, the risk factors and occurrence of progressive coronary dilatation in patients with KD but without medium or giant aneurysms have been insufficiently explored.

Methods: We retrospectively enrolled 169 patients with KD from a tertiary medical center in Taiwan during 2009–2013. Medical records of all patients were reviewed. Echocardiography was performed during the acute KD phase and at 3–4 weeks, 6–8 weeks, 6 months, and 12 months after KD onset. Progressive coronary dilatation was defined as the progressive enlargement of coronary arteries on three consecutive echocardiograms. Logistic regression analysis was conducted to evaluate the potential risk factors for coronary aneurysms and progressive coronary dilatation.

Results: Of a total of 169 patients with KD, 31 (18.3%) had maximal coronary Z-scores of $\geq +2.5$ during the acute KD phase, 16 (9.5%; male/female: 9/7) had coronary aneurysms at 1 month after KD onset, and 5 (3.0%) satisfied the definition of progressive coronary dilatation. Multivariate logistic regression analysis revealed that an initial maximal coronary Z-score of $\geq +2.5$ [odds ratio (OR): 5.24, 95% confidence interval (CI): 1.31–21.3, $P = 0.020$] and hypoalbuminemia (OR: 4.83, 95% CI: 1.11–20.9, $P = 0.035$) were independent risk factors for coronary aneurysms and were significantly associated with progressive coronary dilatation. However, the association between intravenous immunoglobulin unresponsiveness and the development of coronary aneurysms at 1 month after KD onset didn't reach the level of significance ($P = 0.058$).

Conclusions: In the present study, 3% (5/169) of patients with KD had progressive coronary dilatation, which was associated with persistent coronary aneurysms at 1 year after KD onset. Initial coronary dilatation and hypoalbuminemia were independently associated with the occurrence of progressive coronary dilatation. Therefore, such patients may require intensive cardiac monitoring and adjuvant therapies apart from immunoglobulin therapies.

Keywords: Kawasaki disease, Risk factors, Progressive coronary dilatation, Hypoalbuminemia

* Correspondence: mingtailin@ntu.edu.tw

¹Department of Pediatrics, National Taiwan University Hospital and Medical College, National Taiwan University, No. 7, Chung-Shan South Road, Taipei 100, Taiwan

Full list of author information is available at the end of the article



Background

Kawasaki disease (KD) is one of the most common forms of systemic vasculitis in children [1]. Even after intravenous immunoglobulin (IVIG) treatment, coronary arterial lesions (CALs) have been observed in 5%–20% of patients with KD during the acute stage [2–4]. In Taiwan and Japan, CALs have typically been classified into three subgroups (small [<4 mm], medium [4–8 mm], and giant [≥ 8 mm]) based on their diameters during the acute disease phase or at 1 month after disease onset [2, 4]. Coronary artery diameter-based severity is the most significant predictor of late coronary outcomes [5]. We observed that progressive coronary dilatation for at least 2 months was associated with worse late coronary outcomes in patients with KD having medium (4–8 mm) or giant (≥ 8 mm) aneurysms [6]. Several studies [7, 8] have evaluated KD-associated CALs by using body surface area-normalized coronary Z-scores and have demonstrated a significant reduction in coronary Z-scores from the initial values mostly in the first 2–3 months. McCrindle and his colleagues [8] reported some risk factors associated with a greater coronary Z-scores at any time, such as younger age and lower serum albumin levels [8]. However, whether the progressive increase of coronary Z-scores occurs in all KD patients, especially those without CAL or with small aneurysms at their acute phase, remains unclear. Therefore, in the present study, we aimed to determine (1) the maximal coronary Z-score distributions in Taiwanese patients with KD at the acute, subacute, and convalescent phases; and (2) the risk factors for coronary aneurysms and progressive coronary dilatation in Taiwanese KD patients.

Methods

This study was approved by the Institutional Review Board of National Taiwan University Hospital.

Patients

In the present study, KD was diagnosed on the basis of the clinical criteria for KD [9]. Patients with KD who were admitted to our institution between January 2009 and December 2013 and were administered IVIG (2 g/kg \times 1 day or 1 g/kg \times 2 days) within 10 days after fever onset were enrolled in this study. However, patients with KD who had congenital heart disease were excluded from the study. The first day of illness was considered as the first day of fever. Patients with an axillary body temperature of <37.5 °C for >24 h were considered afebrile. The aspirin dosage was reduced to 5 mg/kg/day after defervescence. Medical records of all patients were reviewed, and the manifestations, symptoms, and laboratory data (including serum albumin levels and acute-phase reactants) were obtained as described in

previous studies [5, 6]. Echocardiography was performed in all children during the febrile stage and the subacute phase (3–4 and 6–8 weeks) after fever onset, and the echocardiography frequency subsequently varied depending on CAL severity.

IVIG unresponsiveness was defined as the failure to respond to the initial IVIG dosage and the presence of persistent fever for >24 h or the development of KD-associated recrudescence fever after an afebrile period [1, 4, 5]. Patients unresponsive to IVIG were administered additional IVIG doses.

Measurements

The coronary artery measurements were normalized to the body surface area using the established reference in Taiwanese children [10]. In the current study, we defined “coronary artery dilatation” as maximal Z-score $\geq +2.5$ of any branch of coronary artery [1]. Only the coronary dilatation persisted for more than a month after disease onset were considered coronary aneurysms [5, 6]. The severity of coronary aneurysms was classified as small ($+2.5 \leq Z < +5.0$), medium ($+5.0 \leq Z < 10$) and giant ($Z \geq +10.0$) [11]. CALs and the regression were diagnosed based on 2D echocardiography.

Definition of progressive coronary dilatation

Progressive coronary dilatation was defined as the progressive dilatation of coronary arteries on three consecutive echocardiograms [6]. The coronary Z-score on the second echocardiogram had to be higher than that on the first echocardiogram, and the coronary Z-score on the third echocardiogram had to be 8% higher than that on the first echocardiogram. We defined progressive coronary dilatation based on the 8% increase criterion because a previous study [10] on Taiwanese coronary Z-scores showed interobserver differences of 7.1%, 5.8%, and 5.2% for the left main coronary artery, left anterior descending coronary artery, and right coronary artery, respectively. However, in the current study, the interobserver and intraobserver differences were 6.6% and 6.1%, respectively.

Statistical analysis

Patient data are expressed as counts, percentages, medians with interquartile ranges (IQRs), and means (standard deviations). We used the independent Student *t* test and Fisher exact test for comparing continuous and categorical variables, respectively. Nonnormal variables were analyzed using the Mann–Whitney nonparametric test. A *P* value of <0.05 was considered statistically significant. The risk factors for coronary aneurysms derived from the univariate analysis were used in the subsequent logistic regression analysis. The logistic regression analysis was conducted to evaluate

the potential risk factors for coronary aneurysms and progressive coronary dilatation. All analyses were performed using SPSS Statistics (Version 20.0. IBM Corp, Armonk, NY).

Results

Patient characteristics

Between 2009 and 2013, 175 patients with KD were admitted to our hospital. Of these 175 patients with KD, 6 (3.4%) were excluded because they received IVIG treatments beyond 10 days after fever onset. Finally, 169 patients with KD were enrolled in this study. The median age of these patients at the diagnosis of acute KD was 1.4 years (IQR: 8.1 months–2.5 years), and 99 (59%) were boys. The median duration of fever before the first course of IVIG treatment was 5 days (IQR: 4–6 days). Of the 169 KD patients, 138 (81.7%) were administered a single course of IVIG treatment (1 g/kg/day × 2 days or 2 g/kg/dose × 1 day), 20 (11.8%) received IVIG retreatment, and 11 (6.5%) did not receive IVIG treatment due to defervescence before IVIG administration. Moreover, the enrolled patients did not receive steroid therapies, and none of them died during the study period. Table 1 presents the characteristics of the patients with KD according to their maximal coronary Z-scores during the acute KD phase.

Echocardiography measurements

All enrolled patients underwent echocardiography before receiving IVIG treatment. The median maximal coronary Z-score of any coronary artery during the acute KD phase was 1.60 (IQR: +0.95 – +2.2). Table 1 shows the clinical and laboratory data of 31 and 138 patients with maximal coronary Z-scores of $\geq +2.5$ and $<+2.5$, respectively, during the acute KD phase. The coronary severity during the acute KD phase (before IVIG

treatment) was associated with IVIG responsiveness, hypoalbuminemia, and C-reactive protein (CRP) levels. On the basis of the definition of coronary aneurysms (persistent coronary dilatation for more than 1 month after disease onset), 16 (9.5%) patients had coronary aneurysms (small, $n = 14$; medium, $n = 2$). At the end of follow-up (12 months after fever onset), four (25.0%) patients had small persistent coronary aneurysms. However, coronary aneurysms or progressive coronary dilatation was not observed in 11 patients who did not receive IVIG treatment due to defervescence within 10 days after KD onset.

Risk factors associated with the coronary aneurysms

Univariate analysis revealed three potential risk factors associated with the coronary aneurysms, including initial maximal coronary Z-score of $\geq +2.5$, IVIG unresponsiveness, and serum albumin levels [Table 2].

The median of serum albumin levels were significantly lower in the 16 KD patients with coronary aneurysms (3.4 g/dL, IQR: 2.85–3.55 g/dL) than in those without coronary aneurysms (4.0 g/dL, IQR: 3.6–4.3 g/dL; $P < 0.001$). When hypoalbuminemia was defined by serum albumin levels of <3.5 g/dL, it remained significantly associated with the development of coronary aneurysms (11/16 vs 25/153, $P < 0.001$) in this study.

Multivariate logistic regression analysis was conducted to evaluate the independent effects of an initial maximal coronary Z-score of $\geq +2.5$, hypoalbuminemia, and IVIG unresponsiveness on the development of coronary aneurysms in the 169 patients with KD. An initial maximal coronary Z-score of $\geq +2.5$ and hypoalbuminemia were independent risk factors for coronary aneurysms (odds ratio [OR] of initial maximal coronary Z-score of $\geq +2.5$: 5.24, 95% confidence interval (CI): 1.31–21.3, $P = 0.020$; OR of hypoalbuminemia:

Table 1 Characteristics of patients with and without coronary dilatation during their acute KD phase

	All (169)	Normal (138)	Dilatation (31)	P value
Male gender	99 (59%)	81 (59%)	18 (58%)	0.949
Age (yr)	1.44 (0.67; 2.56)	1.46 (0.71; 2.74)	1.12 (0.36; 2.09)	0.063
IVIG unresponsive	20 (12%)	11 (8%)	9 (29%)	0.001
Days of fever before IVIG use	5 (5; 6)	5 (4.3; 6)	5 (5; 6.3)	0.518
Albumin (g/dL)	3.9 (3.5; 4.3)	4 (3.6; 4.3)	3.5 (3.2; 4.2)	0.03
AST (U/L)	38 (29; 66.5)	37 (29; 71.5)	39.5 (25.3; 56.3)	0.379
CRP (mg/dL)	7.23 (2.22; 14.15)	6.1 (3.26; 11.93)	14.05 (6.38; 18.29)	0.009
WBC (k/ μ L)	13.74 (10.32; 17.56)	13.61 (10.29; 16.94)	15.36 (10.74; 19.64)	0.418
Seg (%)	62.3 (51.3; 73.6)	62.9 (53.5; 73.9)	59 (49.7; 72)	0.391
Hb (g/dL)	11.1 (10.4; 12)	11.2 (10.5; 12)	10.9 (10.4; 11.8)	0.329
PLT (k/ μ L)	333 (260; 412)	328 (260; 405)	343 (253; 454)	0.285

Values are expressed as medians (IQRs) and percentages (%). IVIG intravenous immunoglobulin, AST Aspartate aminotransferase, CRP C-reactive protein, WBC White blood cell, Seg Neutro segment WBC, Hb hemoglobin, PLT platelet

Table 2 Univariate analysis of the risk factors for coronary aneurysms

	Coronary AN (n = 16)	Regression (n = 153)	p-value
Male gender	9 (56%)	90 (59%)	0.842
Age (yr)	0.99 (0.33; 1.86)	1.5 (0.69; 2.7)	0.059
Initial Z-score \geq 2.5	10 (56%)	21 (14%)	<0.001
IVIG unresponsive	8 (50%)	12 (7.8%)	<0.001
Days of fever before 1st IVIG use	5 (5; 7)	5 (4; 6)	0.346
Albumin (g/dL)	3.4 (2.85; 3.55)	4.0 (3.6; 4.3)	<0.001
AST (U/L)	45 (25; 87)	38 (29; 60.3)	0.885
CRP (mg/dL)	12.15 (6.35; 18.18)	6.68 (3.3; 13.37)	0.058
WBC (k/ μ L)	17.79 (9.52; 19.19)	13.65 (10.39; 16.94)	0.426
Seg (%)	63.1 (55.7; 77.5)	61.8 (51.1; 73.5)	0.721
Hb (g/dL)	10.8 (10.4; 11.5)	11.1 (10.45; 12)	0.307
PLT (k/ μ L)	399 (487; 886)	333 (262; 409)	0.965

Values are expressed as medians (IQRs) and percentages (%). IVIG Intravenous immunoglobulin, AST Aspartate aminotransferase, CRP C-reactive protein, WBC White blood cell, Seg Neutro segment WBC, Hb Hemoglobin, PLT Platelet

4.83, 95% CI: 1.11–20.9, $P = 0.035$; OR of IVIG unresponsiveness: 4.63, 95% CI: 0.96–22.3, $P = 0.058$).

Risk factors and implications of progressive coronary dilatation

The coronary Z-scores of six patients increased from $<+2.5$ initially to $\geq +2.5$ at 1 month after KD onset; however, none of these patients exhibited any further increase in their coronary Z-scores on subsequent echocardiographic examinations (Fig. 1). Of the 10 patients with persistent coronary aneurysms at 1 month after KD onset, 5 showed more increased coronary Z-scores at 2 months after KD onset (Fig. 1), thus satisfying the criteria of progressive coronary dilatation on three consecutive echocardiograms. Of the five patients with progressive coronary dilatation, four had persistent coronary aneurysms even at 1 year after KD onset. Compared with the remaining 11 patients without progressive coronary dilatation, 4 patients with progressive coronary dilatation had a higher probability of persistent coronary aneurysms at 1 year after KD onset (0/11 vs 4/5, $P = 0.003$).


Of the 31 patients with KD initial coronary Z-scores of $\geq +2.5$, 5 (16.1%) had progressive coronary dilatation on three consecutive echocardiograms. However, none of the remaining 138 patients with initial coronary Z-scores of $<+2.5$ showed such progression (5/31 vs 0/138; $P = 2 \times 10^{-4}$). Furthermore, of the 36 KD patients with hypoalbuminemia, 5 developed progressive coronary dilatation. Moreover, the patients with normal serum albumin levels did not develop progressive coronary dilatation ($P = 3 \times 10^{-4}$). The incidence of progressive

coronary dilatation did not differ significantly between the IVIG-responsive and IVIG-unresponsive patients with KD (3/138 vs 2/20, $P = 0.11$). To avoid the interaction of risk factors, multivariate logistic regression analysis was conducted to determine the risk factors for progressive coronary dilatation. The results confirmed that an initial maximal coronary Z-score of $\geq +2.5$ (OR: 10.94, 95% CI: 1.14–104.91, $P = 0.038$) and hypoalbuminemia (OR: 9.25, 95% CI: 1.001–88.93, $P = 0.049$) were independent risk factors for progressive coronary dilatation in the patients with KD. However, IVIG unresponsiveness was not significantly associated with progressive coronary dilatation (OR: 1.85, 95% CI: 0.26–13.14, $P = 0.54$).

Discussion

In this study, based on serial echocardiographic measurements, we recognized two independent clinical characteristics (initial maximal coronary Z-score of $\geq +2.5$ and hypoalbuminemia during the acute KD phase) that were significantly associated with coronary aneurysms at 1 month after KD onset as well as progressive coronary dilatation. Progressive coronary dilatation has been insufficiently explored before. McCrindle et al. [8] examined coronary artery involvement in children with KD and observed that if the maximal coronary Z-score is $<+2.5$ on the initial echocardiogram, it might increase above $+2.5$ on subsequent echocardiograms in 6% of patients, which is consistent with our study findings (6/138, 4.3%). Moreover, our recent study reported progressive coronary dilatation for at least 2 months in KD patients with medium (25.5%) or giant (48.1%) aneurysms [6]. Furthermore, the current study confirmed that progressive coronary dilatation can occur in KD patients with small aneurysms (3/14, 21.4%), though with a less probability. In 5 (31.3%) of the 16 patients with coronary aneurysms in the current study, the aneurysms enlarged on three consecutive echocardiographic examinations. Moreover, these five patients were more likely to have persistent coronary aneurysms for more than 1 year compared with those without progressive coronary dilatation (4/5 vs 0/11, $P = 0.003$). These findings support our previous observation that progressive coronary dilatation is associated with worse late coronary outcomes [6].

A recent study reported that 81% of patients with KD who eventually developed coronary aneurysms showed coronary abnormalities on their initial echocardiograms [12]. Studies have proposed the use of adjuvant therapies with agents such as atorvastatin [13], steroids [14, 15], and dalteparin [16] to ameliorate the CALs of patients with KD during the acute KD phase. Friedman et al. [17] demonstrated that the rate of coronary aneurysm regression was significantly higher in patients with KD



receiving IVIG and adjunctive medications than in those not receiving such medications (91% vs 68%, $P = 0.02$). Our present study showed that patients with KD having initial maximal coronary Z-scores of $\geq +2.5$, particularly those with hypoalbuminemia, are susceptible to progressive coronary dilatation. However, additional studies are warranted to elucidate whether IVIG and adjuvant therapies can promote the regression of coronary aneurysms and prevent their progressive dilatation in patients with KD.

Crystal et al. showed that greater coronary Z-scores over the complete study period were significantly associated with greater initial coronary Z-scores [18], which supports the findings of our studies. Previous studies have identified a few risk factors for coronary dilatation or aneurysmal formation [19–21], including late IVIG treatment, IVIG unresponsiveness, and several clinical biomarkers, such as serum albumin levels and CRP levels. In the current study, we further demonstrated hypoalbuminemia during the acute KD phase was also significantly associated with progressive coronary dilatation. In addition, of the 16 patients with coronary

aneurysms at 1 month after KD onset (Fig. 1), 5 showed more increased coronary Z-scores at 2 months after KD onset. Furthermore, All of the five patients with progressive coronary dilatation had hypoalbuminemia (<3.5 g/dL, 100%), indicating that the incidence of hypoalbuminemia was higher in the aforementioned patients than in the remaining 11 patients with coronary aneurysms ($P = 0.012$). These findings may indicate that patients with KD who develop hypoalbuminemia during the acute KD phase, particularly those with coronary Z-scores of $\geq +2.5$, are susceptible to progressive coronary dilatation and may require closer cardiac monitoring and more aggressive treatments using agents such as statins [13] and steroids [14, 15].

However, the reason for the association of serum albumin levels with coronary aneurysms and progressive coronary dilatation remains unclear. Terai et al. [22] reported that IVIG-unresponsive patients with KD had higher vascular endothelial growth factor levels, which might lead to vascular leakage, decreased serum albumin levels, and pericardial effusion. Therefore, hypoalbuminemia is most likely caused by vascular inflammation and

thus is associated with coronary aneurysms and progressive dilatation in patients with KD.

Previous studies have reported CRP as one of the risk factors for IVIG unresponsiveness [21] and an independent risk factor for initial coronary dilatation [23] and giant aneurysms [24] in patients with KD. However, in the current study, the CRP levels were not significantly associated with coronary aneurysms ($P = 0.058$) or progressive coronary dilatation ($P = 0.54$). Our earlier study revealed that low-grade inflammation was associated with persistent CALs in patients with KD [25]. Therefore, we investigated the association between progressive coronary dilatation and the changes in inflammatory biomarkers (CRP levels, white cell count, and neutrophil percentages) during the acute febrile and subacute phases. However, none of the changes in the three inflammatory biomarkers were associated with progressive coronary dilatation. Therefore, additional studies are warranted to elucidate the effects of CRP and other KD-associated inflammatory biomarkers, such as interleukin-4 [26] and interleukin-6 [27], on early and late CALs in patients with KD.

Limitations

Our study has several limitations. First, this study was conducted in a single tertiary medical center in Taiwan, which may have resulted in selection bias. Second, this study had a retrospective design, and a limited number of patients were enrolled. Third, information bias may have existed, because ultrasound technicians were not blinded to tentative diagnoses. Finally, we did not analyze the socioeconomic factors, febrile days on initial IVIG, and unmeasured laboratory data, such as alanine aminotransferase and bilirubin levels, which were potential confounders in the current study. Large, prospective cohort studies are necessary to reduce the influence of potential confounders.

Conclusions

Coronary artery dilatation with an initial maximal coronary Z-score of $\geq + 2.5$ and hypoalbuminemia during the acute KD phase are independent risk factors for coronary artery aneurysms and progressive coronary dilatation in the subacute KD phase. These simple indicators may help clinicians in identifying high-risk KD children who may have coronary aneurysms and progressive coronary dilatation and require intensive monitoring and additional therapies.

Abbreviations

CAL: Coronary arterial lesions; CI: Confidence interval; CRP: C-reactive protein; IQR: Interquartile range; IVIG: Intravenous immunoglobulin; KD: Kawasaki disease; OR: Odds ratio

Acknowledgments

This study was supported by the Cardiac Children's Foundation, Taiwan (grant no. CCFT2013-01).

Funding

This study received funding from the Cardiac Children's Foundation, Taiwan. The funder played no role in the study design, data collection, data analysis, data interpretation, or manuscript writing.

Availability of data and materials

The datasets used and analyzed in the current study can be obtained from the corresponding author on reasonable request.

Authors' contributions

M-Y L and HL performed data collection and interpretation and drafted the initial manuscript. CW and GH made substantial contributions to acquisition of data, especially the laboratory and echocardiographic data. C-H C provided statistical assistance. C-A C, SC, and CL managed patient care and the enrollment of eligible patients. LC revised the manuscript critically and provided instruction regarding pediatric infectious disease. JW and MW performed data interpretation. M-T L had full data access and is accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All authors have read and approved the final submission.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

The present study was approved by the Institutional Review Board of National Taiwan University Hospital (reference number, 201411077RIND). Consent to participate was sought from the primary caretakers of all children included in this study.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

¹Department of Pediatrics, National Taiwan University Hospital and Medical College, National Taiwan University, No. 7, Chung-Shan South Road, Taipei 100, Taiwan. ²Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan. ³Medical Information Management Office, National Taiwan University Hospital, Taipei, Taiwan.

Received: 25 January 2017 Accepted: 31 May 2017

Published online: 06 June 2017

References

1. Newburger JW, Takahashi M, Burns JC. Kawasaki disease. *J Am Coll Cardiol*. 2016;67:1738–49.
2. Wu MH, Chen HC, Yeh SJ, Lin MT, Huang SC, Huang SK. Prevalence and the long-term coronary risks of patients with Kawasaki disease in a general population <40 years: a national database study. *Circ Cardiovasc Qual Outcomes*. 2012;5:566–70.
3. Eleftheriou D, Levin M, Shingadia D, Tulloh R, Klein NJ, Brogan PA. Management of Kawasaki disease. *Arch Dis Child*. 2014;99:74–83.
4. JCS Joint Working Group. Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease (JCS 2013). Digest version *Circ J*. 2014;78:2521–62.
5. Lin MT, Sun LC, Wu ET, Wang JK, Lue HC, Wu MH. Acute and late coronary outcomes in 1073 patients with Kawasaki disease with and without intravenous gamma-immunoglobulin therapy. *Arch Dis Child*. 2015;100:542–7.
6. Chih WL, Wu PY, Sun LC, Lin MT, Wang JK, Wu MH. Progressive Coronary Dilatation Predicts Worse Outcome in Kawasaki Disease. *J Pediatr*. 2016;171:78–82. e1

7. de Zorzi A, Colan SD, Gauvreau K, Baker AL, Sundel RP, Newburger JW. Coronary artery dimensions may be misclassified as normal in Kawasaki disease. *J Pediatr*. 1998;133:254–8.
8. McCrindle BW, Li JS, Minich LL, Colan SD, Atz AM, Takahashi M, et al. Coronary artery involvement in children with Kawasaki disease: risk factors from analysis of serial normalized measurements. *Circulation*. 2007;116:174–9.
9. Research Committee on Kawasaki Disease. Report of Subcommittee on Standardization of Diagnostic Criteria and Reporting of Coronary Artery Lesion in Kawasaki Disease. Tokyo, Japan: Ministry of Health and Welfare; 1984.
10. Lin MT, Chang CH, Hsieh WC, Chang CE, Chang YM, Chen YC, et al. Coronary Diameters in Taiwanese Children Younger than 6 Years Old: Z-Score Regression Equations Derived from Body Surface Area. *Acta Cardiol Sin*. 2014;30:266–73.
11. Manlhiot C, Millar K, Golding F, McCrindle BW. Improved classification of coronary artery abnormalities based only on coronary artery z-scores after Kawasaki disease. *Pediatr Cardiol*. 2010;31:242–9.
12. Dominguez SR, Anderson MS, El-Adawy M, Glodé MP. Preventing coronary artery abnormalities: a need for earlier diagnosis and treatment of Kawasaki disease. *Pediatr Infect Dis J*. 2012;31:1217–20.
13. Tremoulet AH, Dutkowski J, Sato Y, Kanegaye JT, Ling XB, Burns JC. Novel data-mining approach identifies biomarkers for diagnosis of Kawasaki disease. *Pediatr Res*. 2015;78:547–53.
14. Sundel R. Clarifying the Role of Corticosteroids in Kawasaki Disease. *JAMA Pediatr*. 2016;170:1140–2.
15. Kobayashi T, Saji T, Otani T, Takeuchi K, Nakamura T, Arakawa H. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. *Lancet*. 2012;379:1613–20.
16. Inamo Y, Saito K, Hasegawa M, Hayashi R, Nakamura T, Abe O. Effect of dalteparin, a low-molecular-weight heparin, as adjunctive therapy in patients with Kawasaki disease: a retrospective study. *BMC Pediatr*. 2014;14:27. doi:10.1186/1471-2431-14-27.
17. Friedman KG, Gauvreau K, Hamaoka-Okamoto A, Tang A, Berry E, Tremoulet AH, et al. Coronary Artery Aneurysms in Kawasaki Disease: Risk Factors for Progressive Disease and Adverse Cardiac Events in the US Population. *J Am Heart Assoc*. 2016;5:e003289.
18. Crystal MA, Manlhiot C, Yeung RS, Smallhorn JF, McCrindle BW. Coronary artery dilation after Kawasaki disease for children within the normal range. *Int J Cardiol*. 2009;136:27–32.
19. Yellen ES, Gauvreau K, Takahashi M, Burns JC, Shulman S, Baker AL, et al. Performance of 2004 American Heart Association recommendations for treatment of Kawasaki disease. *Pediatrics*. 2010;125:e234–41.
20. Nakamura Y, Yashiro M, Uehara R, Watanabe M, Tajimi M, Oki I, et al. Use of laboratory data to identify risk factors of giant coronary aneurysms due to Kawasaki disease. *Pediatr Int*. 2004;46:33–8.
21. Kobayashi T, Inoue Y, Takeuchi K, Okada Y, Tamura K, Tomomasa T, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. *Circulation*. 2006;113:2606–12.
22. Terai M, Honda T, Yasukawa K, Higashi K, Hamada H, Kohno Y. Prognostic impact of vascular leakage in acute Kawasaki disease. *Circulation*. 2003;108:325–30.
23. Kuwabara M, Yashiro M, Kotani K, Tsuboi S, Ae R, Nakamura Y, et al. Cardiac lesions and initial laboratory data in Kawasaki disease: a nationwide survey in Japan. *J Epidemiol*. 2015;25:189–93.
24. Koyanagi H, Nakamura Y, Yanagawa H. Lower level of serum potassium and higher level of C-reactive protein as an independent risk factor for giant aneurysms in Kawasaki disease. *Acta Paediatr*. 1998;87:32–6.
25. Chen YC, Shen CT, Wang NK, Huang YL, Chiu HH, Chen CA, et al. High Sensitivity C Reactive Protein (hs-CRP) in Adolescent and Young Adult Patients with History of Kawasaki Disease. *Acta Cardiol Sin*. 2015;31:473–7.
26. Burns JC, Shimizu C, Shike H, Newburger JW, Sundel RP, Baker AL, et al. Family-based association analysis implicates IL-4 in susceptibility to Kawasaki disease. *Genes Immun*. 2005;6:438–44.
27. Fujimaru T, Ito S, Masuda H, Oana S, Kamei K, Ishiguro A, et al. Decreased levels of inflammatory cytokines in immunoglobulin-resistant Kawasaki disease after plasma exchange. *Cytokine*. 2014;70:156–60.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit

